small molecule glp 1 In the ACHIEVE-1 phase 3 trial, the oral small-molecule GLP-1 receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes Orforglipron, an Oral Small-Molecule GLP-1
Pay in 4 interest-free payments of $6.65 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9

















:max_bytes(150000):strip_icc()/normal-bowel-movements-1942606-v1-5c3b856a46e0fb00014b2036.png)






